Price
No data yet.
Social Signal Score
Revenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jasbir S. Seehra
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 92
- Beta
- 1.01
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 5.90
Financials
Revenue
$0.00-100.0%Net Income
$-28.71MEBITDA
$-28.31MFree Cash Flow
$-20.58MEPS (diluted)
$-1.45Shares Outstanding (diluted)
19.80M+122.9%Operating Expenses
$30.94MCash & Debt
$257.61MRevenue by Segment (annual)
$244.06MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $244.06M | $87.01M | $2.34 |
| 2024 | $3.55M | $-187.35M | $-5.00 |
| 2023 | $151.0K | $-152.99M | $-5.20 |
| 2022 | $0.00 | $-104.68M | $-4.15 |
| 2021 | $20.10M | $-58.74M | $-2.52 |
| 2020 | $0.00 | $-45.36M | $-2.93 |
| 2019 | $10.00M | $-12.34M | $-1.39 |
| 2018 | $10.00M | $-1.33M | $-0.15 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.43
- Implied price
- $30.91
- Return from $11.01
- 22.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $15.37 — today's price is already 28.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 5 | 7 | 9 | 11 | 13 |
|---|---|---|---|---|---|
| -2.0% | -0.8% | 6.1% | 11.6% | 16.1% | 20.1% |
| 3.0% | 4.2% | 11.5% | 17.2% | 22.0% | 26.2% |
| 8.0% | 9.3% | 16.9% | 22.9% | 28.0% | 32.3% |
| 13.0% | 14.4% | 22.3% | 28.6% | 33.9% | 38.4% |
| 18.0% | 19.4% | 27.7% | 34.3% | 39.8% | 44.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100Social Signal Score
Mentions (2)
- Newszacks.com·5h ago·Positive
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk? Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
View source ↗ - Newszacks.com·5h ago·Negative
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
View source ↗
Earnings
Wed, Nov 4(in 2 months)
Consensus estimate $-0.94 per share
Typical surprise +16.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 3$-1.45 vs $-1.34miss
- Thu, May 14$-1.21 vs $-0.92miss
- Wed, Mar 4$-0.86 vs $-0.49miss
- Wed, Nov 5$-0.18 vs $-1.11beat
- Wed, Aug 6$-0.76 vs $-1.14beat
- Tue, May 6$3.62 vs $-0.01beat
Estimates and results for KROS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KROS officers and directors.
- Bought
- $9.5m
- Sold
- $16.5m
11 trades
14 trades
- Tanini Annitasold
- Lerner Lorena Raquelsold
- Cho Esthersold
- Newton Charles W.sold
- Bienaime Jean Jacquesbought
- Bienaime Jean Jacquesbought
- Bienaime Jean Jacquesbought
- Newton Charles W.sold
75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.